Clinical Trials Logo
  1. Home
  2. Lung Cancer Stage IV
  3. NCT03153358

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Lung Cancer Stage IV Clinical Trial

Official title:
Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Clinical Trial Summary

Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression. For multiple metastases in patients with advanced NSCLC, increased local treatment may benefit to prolong patient survival. This study investigated the benefits of icotinib limited systemic disease progression and continuation of Stereotactic Body Radiation Therapy,in patients with metastatic EGFR-mutant NSCLC.

Clinical Trial Description

Lung cancer is the leading cause of cancer morbidity and mortality worldwide. The majority of lung cancer is nonsquamous NSCLC. EGFR tyrosine kinase inhibitors (EGFR-TKI) is a effective first-line treatment for EGFR mutations non-squamous NSCLC treatment.Icotinib is the first EGFR-TKI,and have been proved efficiently in the treatment of lung cancer, and SBRT become a main therapy for the primary lesion,Accordingly, we have come to a scientific hypothesis that icotinib combination with SBRT might be a better treatment strategy for stageIV non-squamous NSCLC patients with EGFR mutation. It can improve the PFS of stage ⅢB/Ⅳ non-squamous NSCLC patients with EGFR mutation . The primary endpoint is disease-free time to progression (PFS). The secondary study endpoint is objective response rate (ORR), disease control rate (DCR),overall survival(OS) safety and quality of life (QOL). Through this study lay the foundation for further exploration of the non-squamous NSCLC first-line treatment in patients with EGFR mutation strategy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03153358
Study type Interventional
Source Sichuan Cancer Hospital and Research Institute
Contact juan li, doctor
Phone +8613880276636
Email dr.lijuan@gmail.com
Status Not yet recruiting
Phase Phase 2
Start date June 2, 2017
Completion date May 2, 2019
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03668496 - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Phase 3
Active, not recruiting NCT03322072 - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating N/A
Recruiting NCT05497973 - Psychosocial eHealth in Advanced Lung Cancer N/A
Recruiting NCT06076005 - Lung Cancer ID (Identity) Study
Recruiting NCT05860296 - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Phase 1/Phase 2
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Completed NCT04825912 - Resilience Measurement in Older Adults With Late-Stage Lung Cancer N/A
Completed NCT03529851 - Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients N/A
Completed NCT03558165 - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Completed NCT03076164 - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Phase 1/Phase 2
Recruiting NCT04595734 - Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Recruiting NCT04519983 - Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs Phase 2
Not yet recruiting NCT05701384 - Lazertinib 160mg in EGFR T790M NSCLC Phase 2
Withdrawn NCT03409341 - Personalizing Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT03728361 - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Phase 2
Not yet recruiting NCT06024941 - Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer Phase 2
Recruiting NCT04669223 - Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion N/A
Recruiting NCT05996263 - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Completed NCT04057196 - Self-System Therapy for Older Adults With Lung Cancer N/A
Recruiting NCT06000358 - The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer N/A